TABLE 1.
Characteristics of the study subjects. Data are presented as n (%) or Mean ± SD as appropriate.
| Characteristics | MD group (n = 62) | ED group (n = 63) | p-value |
| Age | |||
| Mean, years | 7.92 ± 2.52 | 8.70 ± 2.27 | > 0.05 |
| Gender | |||
| Male | 44 (70.97%) | 48 (76.19%) | > 0.05 |
| Female | 18 (29.03%) | 15 (23.81%) | > 0.05 |
| Sensitization status | |||
| Monosensitized | 4 (6.45%) | 2 (3.17%) | > 0.05 |
| Polysensitized | 58 (93.55%) | 61 (96.83%) | > 0.05 |
| Clinical data | |||
| Baseline TASS | 3.03 ± 0.79 | 3.19 ± 0.91 | > 0.05 |
| Baseline TAMS | 5.03 ± 0.18 | 5.00 ± 0.00 | > 0.05 |
| Baseline ACQ | 1.66 ± 0.33 | 1.53 ± 0.44 | > 0.05 |
| Baseline FeNO (ppb) | 29.47 ± 14.01 | 26.08 ± 14.04 | > 0.05 |
| Baseline FEV1 (%) | 86.03 ± 10.05 | 83.63 ± 7.99 | > 0.05 |
| Baseline FEV1/FVC (%) | 91.16 ± 9.07 | 91.11 ± 7.29 | > 0.05 |
p-values designate significant difference between the MD group and the ED group.